The clinical characteristics of fascioliasis in pediatric patients
Çocukluk çağı fasioliyaz olgularımızın klinik özellikleri

Gülsüm İclal Bayhan¹, Ayşegül Taylan Özkan², Yunus Emre Beyhan¹

¹Department of Pediatric Infection, Yüzüncü Yıl University Faculty of Medicine, Van, Turkey
²Department of Medical Microbiology, Hitit University Faculty of Medicine, Çorum, Turkey

Abstract
Fascioliasis is a trematode flatworm infection caused by Fasciola hepatica and F. gigantica. Fasciola hepatica is mesoendemic in Turkey. Six cases of pediatric fascioliasis are presented here. All patients had histories of consumption of various raw vegetables. Four of our patients were at the hepatic phase, and two were at the biliary phase. Except for one patient, all patients had eosinophilia. In three patients, total IgE levels were markedly increased. In these patients, there was an eosinophilic leukemoid reaction accompanied by a high total IgE level. Except for one of our patients, all patients had positive indirect hemagglutination tests. This patient was diagnosed as having fascioliasis with a compatible clinical picture. Except one, all of our patients were completely treated with a single-treatment regimen of triclabendazole; one patient needed re-administration. Only in patient 1, liver enzymes increased after triclabendazole administration because he had taken the medication for longer than prescribed by mistake. The elevation of liver enzymes was not observed in the other patients who received the correct dose. All patients recovered completely with triclabendazole treatment. The patients’ dietary habits, eosinophilia, and markedly elevated IgE levels may be significant predictors for physicians to suspect fascioliasis.

Keywords: Child, eosinophilia, Fasciola hepatica, triclabendazole

Corresponding Author/Sorumlu Yazar: Gülsüm İclal Bayhan
E-mail/E-posta: gibayhan@gmail.com
Received/Geliş Tarihi: 18.02.2018
Accepted/Kabul Tarihi: 10.09.2018

Introduction
Fascioliasis is a trematode flatworm infection caused by Fasciola hepatica and less commonly by F. gigantica. Infections have been reported from all continents, except Antarctica. In Van Province in Turkey, the seroprevalence of fascioliasis was previously reported as 5.6%, comparable to that reported in other regions of Turkey (1). Fasci-
Fascioliasis, like other trematode infections, may present with few or no symptoms. There are a few reported pediatric fascioliasis cases in the literature. Herein, we report our pediatric fascioliasis cases.

**Cases**

We review pediatric patients with confirmed fascioliasis in Yuzuncu Yil University Medical Faculty in Van Province, located in the Eastern region of Turkey. Six pediatric patients were diagnosed as having fascioliasis between March 1<sup>st</sup>, 2014, and April 30<sup>th</sup>, 2016. Fascioliasis was diagnosed a) if eggs were detected in the stool with the patients’ clinical symptoms and signs being compatible with fascioliasis, and/or b) using *Fasciola* spp. indirect hemagglutination test (IHA) (titer: 1/160) with the patients’ clinical symptoms and signs being compatible with fascioliasis. Patients were treated with triclabendazole (10 mg/kg per day for one or two days). All patients were scheduled for a follow-up visit after treatment completion; the first scheduled visit was one week after treatment, and subsequent follow-up visits were scheduled monthly thereafter. Complete blood count and liver enzyme tests were performed during each follow-up visit. Demographic data, epidemiologic history, physical examination findings, laboratory test results, duration of follow-up, and treatment outcomes were recorded in all patients included in the study. Informed consent was obtained from all patients.

There were six pediatric patients with fascioliasis (age range, 4–16 years; mean age, 10.16 years). The patients’ clinical, laboratory, and imaging findings are summarized in Tables 1 and 2. Some important matters not mentioned in the tables are reported here.

Patient 1 had taken triclabendazole for longer than prescribed by mistake. He should have taken it for two days but he continued the medication for four days. Four days after treatment completion, liver enzyme levels increased and bilirubin was normal. During follow-up, liver enzyme levels gradually normalized.

Patient 2 was diagnosed as having biliary fascioliasis and was administered triclabendazole. After one week, the patient presented to our hospital with severe abdominal pain. A physical examination revealed Murphy’s sign, consistent with the diagnosis of acute cholecystitis. Abdominal ultrasonography (US) showed a hydroptic gall bladder and dilated intra- and extrahepatic bile ducts, whereas before treatment, his abdominal US showed a distended gall bladder with very dense content but no hydrops and no intra- or extrahepatic bile duct dilatation. The patient was hospitalized...
and hydrated for three days. His abdominal pain gradually resolved completely. Ten days later, a follow-up abdominal US was performed, and the findings were normal.

Patient 3 presented with arthralgia. He had a 10-day history of shoulder, knee, and back pain. He denied having a cough, sputum or dyspnea. He had severe eosinophilia. A chest X-ray showed perihilar and pericardial interstitial infiltration in both lungs. Thoracic computed tomography (CT) imaging showed multiple, peripherally localized nodular lesions, with surrounding ground-glass opacity or halo in the superior lobes of both lungs, indicating Löeffler’s syndrome (Fig. 1).

Patient 4 was referred to our hospital with a preliminary diagnosis of an abdominal mass. Ultrasonography (US) indicated a higher possibility of *F. hepatica* than of mass lesions. The patient underwent liver biopsy, and a pathologic examination of the specimen revealed severe mixed inflammatory infiltrates of eosinophils and lymphocytes and necrotic foci surrounded by histiocytes. Triclabendazole was administered for two days. Follow-up US performed three months later revealed that the hepatic mass lesion had become significantly smaller but remained in residual quantities. After the second triclabendazole treatment, the residual lesion completely disappeared.

Patient 5 presented with abdominal pain for one week. He was diagnosed as having hepatic fascioliasis and was administered triclabendazole.

Patient 6 presented with abdominal pain, poor appetite, and fever. The patient’s abdominal pain was very disturbing and woke him up at night. He had hepatic fascioliasis accompanied by Löeffler’s syndrome (Fig. 2).

**Discussion**

*Fasciola* genus includes species of liver flukes that live inside the bile ducts of sheep, cattle, buffalo, goat, donkey, horse, and rabbit, and *Fasciola* spp. eggs get scattered to the environment by these animals’ stools. Fascioliasis is transmitted to humans through the consumption of raw plants contaminated with metacercariae. Typically, un-
cooked aquatic plants are reportedly responsible for fascioliasis transmission, particularly watercress. However, several terrestrial plants have also been reported to cause transmission of fascioliasis. Other reported foods are lettuce, alfalfa, spinach, spearmint, arugula, leek, and several other green leafy plants that typically grow near infected animals (2). These plants grow near the water channels or need frequent irrigation before they can be sold; thus, they can be contaminated by the metacercariae-carrying water used for irrigation. Drinking contaminated fresh water from streams is another risk factor (2). Van is a province where livestock is very common, particularly sheep and cattle. Here, people traditionally collect various herbs from the paddies in the spring and eat them. Owing to animal husbandry and the consumption of organic plants being common in Van Province, there is a prevalent risk for fascioliasis transmission to humans. One of our patients had a history of watercress consumption, other patients reported that they consumed various raw vegetables.

Early diagnosis of fascioliasis is difficult because of the biphasic nature and long latency period of the disease. Four of our patients were at the hepatic phase, and two were at the biliary phase. Abdominal pain is the most common symptom in the course of fascioliasis; other frequently seen symptoms include fever, appetite loss, weight loss, fatigue, myalgia, and arthralgia (1, 4). Compatible with the currently available literature, the most common presentation and the chief symptom in our patients was abdominal pain. At the biliary phase, eggs can generally be detected in the stool of patients; however, in both our patients at the biliary phase, stool did not contain Fasciola spp. eggs. If the infection load is low, fewer eggs are released in the stool. Also, in the biliary phase, eggs can be absent in the stool because the fluke has not adapted to the host and has thus not begun the reproduction cycle at this stage (5).

Parasitic infection is the most common cause of eosinophilia and can also induce an eosinophilic leukemoid reaction. The normal mean peripheral blood eosinophil count is 500 cells/µL, and eosinophilia is defined as mild (500–1500 cells/µL), moderate (1500–5000 cells/µL), and severe (>5000 cells/µL). If the white blood cell (WBC) count is >30,000/mm³, with >30% eosinophils, this situation is defined as an eosinophilic leukemoid reaction, which can lead the patient to undergoing unnecessary bone marrow aspiration (6). Eosinophilia is a common laboratory finding in fascioliasis that occurs most commonly during the migratory phase of the parasites and was reported in 70.8–89.9% of all fascioliasis cases (1, 6). All our patients, except one who had biliary fascioliasis, had eosinophilia, and three had eosinophilic leukemoid reactions. Patients with eosinophilia have to be carefully investigated for fascioliasis because it presents with non-specific symptoms.

Elevation of liver enzymes levels may occur in the course of fascioliasis (4). In two of our cases, liver enzymes were elevated at presentation. Both these cases were of biliary fascioliasis. IgE levels are usually elevated in fascioliasis. It was reported that IgE levels were positively correlated with the egg load and clinical condition (7). Three of our patients with hepatic fascioliasis co-occurring with eosinophilic leukemoid reactions also had significantly increased total IgE levels. Like eosinophilia, a significantly high IgE level without an underlying allergic disease may also make the physician suspect fascioliasis.

The diagnosis of fascioliasis is usually confirmed in serologic tests such as IHA and enzyme-linked immunosorbent assay (ELISA). Except one of our patients (patient 1), all of the other patients had positive IHA. Patient 1 was diagnosed as having fascioliasis with a compatible clinical picture. The predictive values of the serologic tests for
diagnosing fascioliasis are quite high, even though they may give false-positive results due to light infections (8). A pathologic examination is generally not necessary for diagnosis. Pathologic features of hepatic fascioliasis include cellular infiltration comprising eosinophils, macrophages, lymphocytes, and fibrous tissue, and sometimes *F. hepatica* egg granulomas (9). One of our patients underwent a pathologic examination because of the suspicion of a mass in the liver.

Cholangitis and cholecystitis can primarily develop because of the intermittent obstruction of the biliary system and the resulting inflammatory response owing to the *Fasciola* spp. invasion (2). These conditions can also develop after triclabendazole treatment, as in patient 2. Biliary colic is the most common adverse effect of triclabendazole, which is reportedly related to the expulsion of dead or damaged parasites induced by the drug. Liver enzymes increased after triclabendazole administration only in patient 1 because he had taken the medication for longer than prescribed by mistake. Elevated liver enzymes were not observed in the other patients who received the correct dose. Triclabendazole resistance was reported in the literature (10). Except one, all our patients were completely treated with a single-treatment regimen of triclabendazole; one patient needed re-administration. No resistance to triclabendazole was observed.

Fascioliasis may present with non-specific symptoms; however, the most common symptom is abdominal pain. The patients’ dietary habits, eosinophilia, and markedly elevated IgE levels may be significant predictors for physicians to suspect fascioliasis.

**Informed Consent:** Informed consent was obtained from all patients.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - G.İ.B., Y.E.B.; Design - G.İ.B., Y.E.B.; Supervision - A.T.Ö., G.İ.B.; Data Collection and/or Processing - G.İ.B., Y.E.B.; Analysis and/or Interpretation - G.İ.B., Y.E.B.; Literature Review - A.T.Ö., G.İ.B.; Writing - A.T.Ö., G.İ.B.; Critical Review - A.T.Ö., G.İ.B.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

---

**References**

1. Taş Cengiz Z, Yılmaz H, Dülger AC, Akdeniz H, Karahogacil MK, Çiçek M. Seroprevalence of human fascioliasis in Van province, Turkey. Turk J Gastroenterol 2015; 26: 259–62.
2. Marcos L, Maco V, Samalvides F, Terashima A, Espinosa JR, Gotuzzo E. Risk factors for *Fasciola hepatica* infection in children: a case-control study. Trans R Soc Trop Med Hyg 2006; 100: 158–66.
3. Mas-Coma MS, Esteban JG, Bargues MD. Epidemiology of human fascioliasis: a review and proposed new classification. Bull World Health Organ 1999; 77: 340–6.
4. Chand MA, Herman JS, Partridge DG, Hewitt K, Chiodini PL. Imported human fascioliasis, United Kingdom. Emerg Infect Dis 2009; 15: 1876–7.
5. Mas-Coma MS, Esteban JG, Bargues MD. Epidemiology of human fascioliasis: a review and proposed new classification. Bull World Health Organ 1999; 77: 340–6.
6. Ulger BV, Kapan M, Boyuk A, et al. *Fasciola hepatica* infection at a University Clinic in Turkey. J Infect Dev Ctries 2014; 8: 1451–5.
7. Valero MA, Gironès N, García-Bodelón MA, et al. Anaemia in advanced chronic fasciolosis. Acta Trop 2008; 108: 35–43.
8. Valero MA, Periago MV, Pérez-Crespo I, et al. Assessing the validity of an ELISA test for the serological diagnosis of human fascioliasis in different epidemiological situations. Trop Med Int Health 2012; 17: 630–6.
9. World Health Organization. Schistosomiasis Control Unit. Progress in assessment of morbidity due to *Fasciola hepatica* infection: a review of recent literature. WHO; 1990. Available from: http://apps.who.int/iris/handle/10665/61432.
10. Cwiklinski K, O’Neill SM, Donnelly S, Dalton JP. A prospective view of animal and human Fasciolosis. Parasite Immunol 2016; 38: 558–68.